TY - CHAP M1 - Book, Section TI - Rifamycins A1 - Gruenberg, Katherine A1 - Guglielmo, B. Joseph A2 - Papadakis, Maxine A. A2 - McPhee, Stephen J. A2 - Rabow, Michael W. A2 - McQuaid, Kenneth R. Y1 - 2023 N1 - T2 - Current Medical Diagnosis & Treatment 2023 AB - In addition to its use as a primary agent in the treatment of active and latent tuberculosis, rifampin is used as an adjunct in the treatment of S aureus infections. When used as monotherapy, rifampin is associated with rapid emergence of resistance in staphylococci. However, when added to other primary antistaphylococcal agents, rifampin improves outcomes in the treatment of infected prosthetic hardware. Due to its rapid bactericidal activity, rifampin was hypothesized to be an effective adjunct in the treatment of S aureus bacteremia without hardware present. However, the addition of rifampin to standard therapy for the treatment of S aureus bacteremia does not improve outcomes, including treatment failure, recurrence, or death. Rifampin is also effective for the treatment of latent tuberculosis infection. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/10/09 UR - accessmedicine.mhmedical.com/content.aspx?aid=1193122117 ER -